Stock LIFE LIFECARE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lifecare

Equities

LIFE

NO0010591191

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 15:45:00 20/06/2024 BST 		5-day change 1st Jan Change
2.165 NOK +14.55% Intraday chart for Lifecare +3.10% -51.46%
06-10 Lifecare AS Announces Improved the Read-Out Distance from Sensor to the Read-Out Device CI
06-06 Life Sterilization Protocol Ready for the Production Line CI

Valuation

Fiscal Period: December 2023 2024
Capitalization 1 601.5 254.9
Enterprise Value (EV) 1 601.5 171.8
P/E ratio - -
Yield - -
Capitalization / Revenue 52,031,806 x -
EV / Revenue 52,031,806 x -
EV / EBITDA -18,223,063 x -
EV / FCF -15,447,888 x -
FCF Yield -0% -
Price to Book - -
Nbr of stocks (in thousands) 134,866 134,866
Reference price 2 4.460 1.890
Announcement Date 27/02/24 -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - 1.599 22.13 13.09
EBITDA 1 -8.701 -6.721 -2.439 -15.33 -14.57 -33.38
EBIT 1 -8.73 -6.74 -2.458 -15.93 -17.32 -35.35
Operating Margin - - - -996.22% -78.24% -270.12%
Earnings before Tax (EBT) 1 -8.793 -6.555 -2.608 -15.98 -16.95 -35.32
Net income 1 -8.793 -6.555 -2.608 -15.88 -17.48 -35.26
Net margin - - - -992.87% -78.96% -269.43%
EPS 2 -0.1087 -0.0810 -0.0321 -0.1620 -0.1483 -0.2930
Free Cash Flow - - -2.367 -13.91 -13.2 -28.72
FCF margin - - - -869.65% -59.64% -219.48%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 14/05/19 01/06/20 20/04/21 21/04/22 28/03/23 10/04/24
1NOK in Million2NOK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2023 Q4
Net sales 1 - 2.568 5.152
EBITDA 1 - -6.055 -14.54
EBIT 1 - -6.658 -15.32
Operating Margin - -259.32% -297.27%
Earnings before Tax (EBT) - - -
Net income -8.165 -7.029 -
Net margin - -273.75% -
EPS -0.0690 - -
Dividend per Share - - -
Announcement Date 23/08/23 14/11/23 27/02/24
1NOK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025
Net Debt 1 - - -
Net Cash position 1 - 83.1 -
Leverage (Debt/EBITDA) - - -
Free Cash Flow -38.9 - -
ROE (net income / shareholders' equity) - - -
ROA (Net income/ Total Assets) - - -
Assets - - -
Book Value Per Share - - -
Cash Flow per Share - - -
Capex 1 0.82 15 40
Capex / Sales 7.13% - -
Announcement Date 27/02/24 - -
1NOK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LIFECARE Stock Lifecare
-51.46% 24.12M
MODERNA, INC. Stock Moderna, Inc.
+36.74% 51.07B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.86% 38.78B
LONZA GROUP AG Stock Lonza Group AG
+35.31% 38.61B
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 27.32B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.09% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-18.97% 19.46B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+40.90% 13.58B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.48% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.04% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LIFE Stock
  4. Financials Lifecare